Posted by Michael Wonder on 21 Apr 2017
Proposal for various medicines in the neurology, immunology and nephrology therapeutic areas
21 April 2017 - PHARMAC is seeking feedback on a proposal relating to certain medicines in the neurology, immunology and nephrology therapeutic areas to take effect from 1 July 2017.
In summary:
- Midazolam injection (Pfizer) would be available on a Practitioners Supply Order for use in status epilepticus.
- Infliximab (Remicade) hospital restrictions would be widened to include treatment of neurosarcoidosis and Behçet’s disease, and the ocular inflammation criteria would be amended.
- Enoxaparin (Clexane) access would be widened to include use during home haemodialysis.
